Clinical Oncology

[The indication for surgical resection in secondary liver malignancies - New therapeutic approaches]

LUKOVICH Péter1, PŐCZE Balázs1

AUGUST 28, 2020

Clinical Oncology - 2020;7(3)

[During the last decade liver surgery underwent major improvement: mortality rates reduced meanwhile new surgical approaches converted surgeons’ consideration on many advanced cases likely to be resectable. Liver is the most frequent site for tumor metastases and liver metastasis surgery experienced major changes as well. As long as liver resection related mortality rates have decreased indication for operative treatment of liver metastasis with certain primary tumors (stomach, pancreas) gained reconsideration and became reasonable. New surgical methods and approaches (laparoscopy, portal vein embolization) came into everyday application meantime several researches were completed enabling oncological aspect interpretation. Laparoscopy is a proven rational way of approach not only in cases of primary but metastatic liver tumors too: short and long term survival rates and oncological results are comparable with the results of open surgery. Although reports on large number series have not yet been published, it seems that practice of laparoscopy can bring increased number of cases where resection of primary tumor and synchronous liver metastasis can be performed simultaneously. Treatment strategies including surgical procedure overwhelm results of schemes planned with chemotherapy lines only even for patients suffering from advanced metastatic disease with necessary extended liver resection together with major vessel resection or for those who require liver resection following portal occlusion method. Consent opinion in best therapeutic option by oncologist and surgeon is essential to reach optimal liver metastasis patient treatment.]

AFFILIATIONS

  1. Szent János Kórház, Sebészeti Osztály, Budapest

COMMENTS

0 comments

Further articles in this publication

Clinical Oncology

[Az Amerikai Klinikai Onkológiai Társaság 2020. évi kongresszusának legfontosabb újdonságai]

ANDRÁS Csilla

Clinical Oncology

[The hormonal therapy of breast cancer]

VÉGH Éva

[Breast cancer will be diagnosed in 12% of women in well-developed countries over the course of their lifetimes. This review focus on current approaches and strategies of systemic endocrine therapy of breast cancer. Breast cancer can be divided into three main subgroups based on the presence and absence of molecular markers (ER, PR, HER2 receptors). For patients without metastases the therapeutic goals are preventing the locoregional and distant recurrence. The length of adjuvant hormonal treatment is an important question in the everyday oncological practice. For patients with metastatic breast cancer the goal of the therapy is prolonging life, keep quality of life and palliating cancer symptoms. Patients with hormone receptor positive (HR+) tumours receive endocrine therapy, in monotherapy or in combination. As the result of new therapeutic approaches and of international drug development, HR+ breast cancer patients have more and more therapeutic options in case of early breast cancer as well as in metastatic settings.]

Clinical Oncology

[Complex treatment of head and neck cancers – overview]

DÁNOS Kornél, TAMÁS László

[Treatment of head and neck squamous cell carcinomas (HNSCC) is exceptionally complex, requiring the close cooperation of the head and neck surgeon, radiation oncologist and medical oncologist. Excellent tumor control should be our primary goal, however, the selection of treatment should not only be guided by oncologic radicality but by the need of satisfactory quality of life (as most local therapies affect respiratory, swallowing and/or speech function), too. Based on the appropriate diagnostic workup, these cancers are classifi ed into early, locoregionally advanced or recurrent/metastatic stages. Each category requires different treatment modalities, further complicated by the localization of the primary tumor and its metastases, performance status of the patient, comorbidities, and the biology of the lesion. In the present review, the authors summarize the basics of the therapy of head and neck cancers.]

Clinical Oncology

[ESMO Clinical Research Observatory (ECRO). Improving the effi ciency of clinical research through rationalisation of bureaucracy]

PEREZ-GRACIA Luis Jose, AWADA Ahmad, CALVO Emiliano, AMARAL Teresa, ARKENAU Hendrik-Tobias, VIKTOR Gruenwald, BODOKY Gyorgy, LOLKEMA P Martijn, NICOLA Di Massimo, PENEL Nicolas, VERA Ruth, SANMAMED F Miguel, DOUILLARD Jean-Yves

Clinical Oncology

[Importance of hypoxia in tumor progression: road to Nobel price and novel therapeutic opportunities]

KOPPER László, SEBESTYÉN Anna, TÍMÁR József

[It is now evident that cancer hypoxia is one of the new hallmark of cancer due to its consequences in gene expression, metabolism and biology. The importance of cancer hypoxia was recognized by the Nobel-price award in 2019. There are three major causes of cancer hypoxia: insuffi cient vascularization, systemic hypoxia of the host and constitutive activation of oncogene driven signaling pathways, all leading to a unique form of genetic reprogramming by HIF transcription factors. The consequences of HIF activation in cancer is the angiogenic phenotype, a new metabolic profi le and an immunsuppressive microenvironment. Furthermore, cancer hypoxia and the cellular adaptation lead to therapy resistance. Accordingly there is an urgent need to develop target therapies of hypoxia to improve effi cacies of various therapeutic modalities.]

All articles in the issue

Related contents

Lege Artis Medicinae

[Laparoscopic varicocelectomy]

HOLMAN Endre, TÓTH Csaba, PÁSZTOR Imre, FICSÓR Ervin, PAPP Ferenc

[ With the spreading use of the laparoscope in the urological surgery laparoscopic varicocelectomy may become an alternative treatment of varicocele. The method can be advantageous mainly for patients with bilateral cases compared to the open operation. The authors report on two cases that have been the first urological laparoscopic operations in Hungary.]

Clinical Oncology

[Ablation of liver cancer]

DOROS Attila

[Ablative therapies of the malignant liver tumors are used frequently all over the world. It is a very well tolareted minimally invasive treatment, followed by a short observation period. Patients might be sent home within 24 hours. Nowadays, there is suffi cient data supporting its effectiveness in the treatment of early primary liver cancer, equalling the results of surgical resection. The situation is different in liver metastasis, especially from coloectal cancer. In these cases ablative techniques have a supporting role, limiting their action on the multimorbid patients and small non-resectable tumors. These facts and trends - worldwide and in Hungary - are discussed, focusing on effectiveness, places in therapeutic protocols and domestic diffi culties.]

Clinical Oncology

[Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra]

FIZAZI K, JENKINS C, TANNOCK IF

[Following the results of the TAX-327 study, questions have been raised as to whether administering chemotherapy to patient with prostate cancer before symptomatic disease progression when receiving standard hormonal treatment can improve the duration and quality of survival. The GETUG-AFU-15 and CHAARTED studies assessed the effi cacy and tolerability of androgen deprivation therapy (ADT) with or without docetaxel in patients with metastatic hormone-naive prostate cancer. Both studies included a mix of patients with de novo metastatic disease (~75%) and patients with metastases following treatment of localized disease. A short course of ADT was allowed in both trials prior to accrual. Key differences between the two studies include the number of patients with high-volume metastases (GETUGAFU- 15: 52%; CHAARTED: 65%) and number of docetaxel cycles (GETUG-AFU-15: up to nine cycles; CHAARTED six cycles). Both studies reported an improvement in progression-free survival with docetaxel plus ADT versus ADT alone. The GETUG-AFU-15 did not fi nd a signifi cant difference in the primary end point of overall survival (OS) [hazard ratio (HR) 0.9 (95% confi dence interval (CI) 0.7-1.2); P = 0.44] for ADT plus docetaxel versus ADT alone. The CHAARTED study met the primary end point of OS [HR 0.61 (95% CI 0.47-0.80); P = 0.0003], and in a subset analysis reported the greatest improvement in OS for patients with high-volume disease [HR 0.60 (95% CI 0.45-0.81); P = 0.0006]. The following review debates the results from the GETUG-AFU-15 and CHAARTED studies and asks whether medical practice should be changed for patients with metastatic hormone-naive prostate cancer based on the results of one positive study.]

Lege Artis Medicinae

[Treatment of endodermal thyroid cancers]

ÉSIK Olga, NÉMETH György

[Following staging procedures, differentiated thyroid cancers i. e. papillary and follicular carcinomas, are surgically treated with intra- or extracapsular total thyroidectomy (depending on the anatomical extent of the disease) and selective lymphnode dissection. Postoperative complementary use of adjuvant external and systemic radiotherapy is the general practice. External irradiation decreases local/regional relapses in all cases. Radioiodine treatment decreases local/regional/ distant recurrences in cases of tumour cells capable of iodine uptake. Life-long thyroxine medication is required, with a TSH-suppressive dose for relapse prevention and hormone substitution. This treatment regimen, a careful follow-up, and adequate rescue therapy are the prerequisites of the generally excellent patient prognosis, i. e. a survival probability measurable in decades. In anaplastic carcinoma following extracapsular total thyroidectomy and lymph node dissection, external irradiation is always indicated. Chemotherapy has a benefical effect on survival. Hormone replacement therapy is necessary to substitute for the missing metabolic effect of the thyroid. This combined modality treatment leads to some improvement with regard to the prognosis of this poor-risk type of cancer. ]